Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
8,585 total articles
Corpay's market cap ($22.9B) understates the optionality created by a $10.7B‑valued cross‑border JV and the AvidXchange acquisition. Fundamentals (FCF $1.31B, ROE 33%) support a valuation re‑rating; trade plan favors a mid‑term long with strict risk controls.
Nurix's deal with Roche de-risks the commercial path for bexobrutideg (NX-5948) and brings $700M upfront plus up to $2.3B in milestones. With strong Phase 1 data, a planned Phase 3 start by mid-2026, and a $1.74B market cap, NRIX is a candidate for a mid-term re-rating. Trade plan provided with entry, stop, and target tied to fundamentals and known…
Eaton is a deeply entrenched power-management play exposed to a multi-year data center build cycle. With a $148.3B market cap, strong Q1 organic growth and a book-to-bill over 1, the stock offers a mid-term swing opportunity to capture revenue recognition and multiple expansion as projects convert. Valuation is rich, so the trade uses tight risk co…
Pursuit Trades as a controlled long on limited supply and travel recovery: market cap ~$1.27B, float ~20.2M shares, EV/EBITDA ~12.9. Enter near $46.50, stop $41.00, target $60.00 for a long-term (180 trading days) position. Risks include high P/E, negative free cash flow, cyclical leisure demand and short‑interest-driven volatility.
Sony is trading near $20.84 with a $125.2B market cap after a year of headline-driven weakness. Short-term memory cost pressures and PS5 price hikes have scared investors, but the company’s diversified, high-margin music and imaging franchises plus growing recurring royalty streams suggest the market is underappreciating durable earnings power. I r…
Intel is trading near $116.56 after a dramatic recovery from its 2025 lows. The company's foundry business is now material to the top line, and recent reports of large customer interest create a plausible path to earnings normalization. Valuation is stretched (EV/sales ~10.5, negative EPS), so this is a high-risk, event-driven trade: size it like a…
BHP is a high-quality diversified miner trading at $85.38 with a $216.7B market cap, a 3.1% yield and a P/E ~21. Near-term headlines around Simandou and project timing are pressuring sentiment, but fundamentals - strong cash generation across copper, iron ore and coal - argue for buying dips. This trade recommends entering on weakness around $82.50…
First National Bank Alaska (FBAK) is a well-run regional bank with strong profitability, consistent dividends and prestigious national recognition. At a $1.06B market cap and a $320 stock price, the market is pricing near perfection. Technical momentum is soft, short interest and short-volume are elevated, and the stock sits close to its 52-week hi…
NICE collapsed after a Q1 EPS miss and soft near-term guidance. That sell-off created a rare entry where valuation (PE ~10, PB ~1.45) and institutional buying contrast with bearish price action. This is a mid-term, defined-risk long that targets mean reversion and AI backlog recovery while respecting execution risks.
Figure Technology (FIGR) just posted 113% YoY consumer loan marketplace volume growth in Q1 and guided even higher. The market has punished the stock from its $78 52-week high to the $27 area, leaving a tradeable long opportunity: buy $27.30, stop $24.50, primary target $45.00 over a 180 trading-day horizon. Catalysts include the $717M Kiavi acquis…
UiPath reported 17% revenue growth and its first GAAP operating profit in Q1, yet the stock has been punished on AI-token fears and cautious near-term guidance. At $10.75 and a market cap near $5.57B, the shares trade at ~3.3x P/S and ~17x P/E with an attractive free cash flow yield. This trade idea recommends a long with a clear entry, stop and $1…
Syndax (SNDX) has moved from early commercial startup to a company generating meaningful revenue: two approved oncology therapies now produce roughly $172.4M in annual sales. The market is pricing growth but not fully crediting duration and geographic expansion of Revuforj (revumenib) and companion programs. With EV/Sales ~6.6 and a market cap of ~…
Kimbell Royalty Partners offers a compelling income play: a recent $0.41 quarterly distribution, production beating guidance, and conservative leverage (1.6x net debt/EBITDA). Valuation looks attractive on cash-flow multiples but mixed on earnings, so this is a buy only with a disciplined entry and a clear stop.
Nano Labs (NA) is a sub-$50 million market cap semiconductor shop that designs high-throughput AI chips and related infrastructure. At $2.07 the stock looks cheap on headline multiples (P/E ~2.1, P/B ~0.42) and has a tight float, recent insider buying, and growing short interest that can amplify moves. This is a speculative long trade for traders w…
HENSOLDT (HAGHY) is an underappreciated European defense-sensors specialist whose share price sits well below last year's peak despite solid strategic positioning in radar, optronics and additive electronics. With a market cap of roughly $10.3 billion and industry-specific catalysts ahead, the stock is a pragmatic long for investors willing to acce…
Brookfield Renewable (BEP) looks like the clean-power play that quietly benefits from the AI-driven surge in electric demand. The stock yields ~4.3%, trades well below its 52-week high, and sits on a $24.2B market cap — a reasonable entry for a swing trade that combines income with asymmetric upside if data-center and distributed-energy contracts a…
SharpLink (SBET) is essentially an institutional-grade Ethereum treasury with a tiny operating business attached. With 868,699 ETH on the balance sheet and rising staking revenue, the stock behaves like a leveraged play on ETH price cycles. Technicals show oversold momentum and valuation metrics (price-to-book ~0.59) imply significant optionality i…
Modine Manufacturing sits at the intersection of an AI-driven capex cycle and specialized thermal engineering. A recent hyperscale contract and a planned spinoff make Modine a high-growth industrial exposure; the stock's pullback creates a defined-risk swing trade to capture re-rating as contract revenue ramps. Risks include valuation, execution, a…
Marvell (MRVL) is trading like a failed growth story after a volatile few days, but the fundamentals supporting its data-center franchise - high-margin networking and custom silicon - remain intact. With a market cap near $221B, strong cash generation and low leverage, this is a disciplined swing trade to buy a meaningful pullback into $260 with a …
Sanmina's $3B purchase of ZT Systems and the resulting preferred-manufacturer status with major cloud AI customers is already moving the needle. Revenue beats and rising free cash flow give the company optionality to scale U.S. capacity; valuation is rich but not frothy versus growth profile. This trade lays out a disciplined long entry at current …
UFP Industries (UFPI) looks cheap relative to its cash-generative profile and low leverage. Near-term headwinds could keep shares under pressure, but an entry around current levels gives asymmetric upside over the next 180 trading days if housing and margin trends normalize.
BP's recent leadership shuffle and emerging organizational reset create a clearer line of sight on capital allocation. With a $112B market cap, a 4.6% dividend yield, and technicals stabilizing, we upgrade BP to a buy for investors seeking income plus upside from valuation re-rating. Trade plan included for three horizons.
Marvell checks the boxes for a high-upside AI infrastructure trade: direct exposure to hyperscaler networking and storage demand, healthy cash generation ($1.66B FCF last reported), low leverage (debt/equity 0.27) and a stock price that has already priced in much of the upside but still leaves room if design wins stick. This trade idea lays out a c…
GoGold (GLGDF) is a sub-$1B gold developer/producer with near-term production, a deep exploration pipeline and rising market interest in permitted projects. With a market cap of ~$943M, modest valuation multiples and growing short interest, the stock looks set up for a mid-term swing if a handful of permit and production catalysts arrive. Trade pla…
ResMed is trading below its shorter-term moving averages after a recent pullback, but the fundamental case remains intact: diversified revenue streams, double-digit top-line growth, and strong free cash flow. The risk that GLP-1 weight-loss drugs will materially shrink ResMed's addressable market is overstated. Enter a mid-term long with a tight st…
